Breckenridge Pharmaceutical, Inc recalls Duloxetine Delayed-Release Capsules
FDA Class II
FDA classified this recall as Class II: the product may cause health problems that are temporary or can be treated; the chance of serious harm is remote.
- Hazard
- CGMP Deviations: presence of N-nitroso-duloxetine impurity above FDA recommended interim limit.
- Products
-
- Duloxetine Delayed-Release Capsules
- Where it was sold
-
Nationwide in the US
Nationwide
- Units affected
- 163,883 bottles
- About this recall
- Duloxetine Delayed-Release Capsules, USP, 30mg, Rx Only, 90-count bottles (NDC 51991-747-90) Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922.